Curated News
By: NewsRamp Editorial Staff
October 13, 2026
SS Innovations Submits FDA Response for SSi Mantra Robotic System
TLDR
- SS Innovations advances FDA review for SSi Mantra, positioning itself to enter the U.S. surgical robotics market with a cost-effective alternative.
- SS Innovations submitted additional data to the FDA, including clinical studies, to support its 510(k) for the SSi Mantra system for cholecystectomy.
- SS Innovations aims to make robotic surgery affordable and accessible globally, potentially improving surgical outcomes for more patients.
- The SSi Mantra features modular arms, 3D 4K visualization, and telesurgery capability, with clinical validation in over 190 procedure types in India.
Impact - Why it Matters
This development matters because it brings SS Innovations one step closer to entering the U.S. surgical robotics market, which is currently dominated by a few major players. The SSi Mantra system's potential FDA clearance could offer hospitals and surgeons a more affordable and accessible option for robotic-assisted surgery, ultimately benefiting patients through increased access to minimally invasive procedures. The successful submission of the FDA response and the anticipation of a review completion in early 2027 signals progress in regulatory approval, which could lead to commercialization and adoption in the U.S., impacting the competitive landscape and potentially reducing healthcare costs associated with robotic surgery.
Summary
SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has announced a significant step forward in its quest to bring its SSi Mantra surgical robotic system to the U.S. market. On Oct. 5, 2026, the company submitted its response to the U.S. Food and Drug Administration's (FDA) request for additional information regarding its 510(k) submission. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. This submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market.
SS Innovations is dedicated to making robotic surgery affordable and accessible globally. Its product range includes the proprietary SSi Mantra system and the comprehensive suite of SSi Mudra surgical instruments, which support a variety of procedures including cardiac surgery. The SSi Mantra is a modular, multi-arm system featuring advanced technology such as 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for patient information. It also offers optional telesurgery capability via the SSi MantrAsana tele-surgeon console. The system utilizes over 40 different types of robotic endo-surgical instruments and has been clinically validated in India in more than 190 different types of surgical procedures. For more information, visit https://ibn.fm/A6dJ8.
The news was distributed through TechMediaWire, a specialized communications platform focused on pioneering companies driving the future of technology. TechMediaWire is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire and other services to reach target markets. The platform offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, SS Innovations Submits FDA Response for SSi Mantra Robotic System
